{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:58:11Z","timestamp":1753891091743,"version":"3.41.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Myelin oligodendrocyte glycoprotein (MOG) antibody-associated diseases (MOGAD), which has been recognized as a distinct entity in patients with neuromyelitis optica spectrum disorders, often presents with acute disseminated encephalomyelitis (ADEM) symptoms in pediatric patients. Appropriate treatment based on accurate diagnosis is challenging in relapsing pediatric patients with MOGAD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>An 11-year-old girl experienced relapses four times, exhibiting brainstem symptoms, an ADEM episode, seizures, and optic neuritis (ON). She was initially diagnosed with multiple sclerosis and received interferon beta-1a therapy with a mild effect on relapse suppression. She was then transferred from the pediatric department to the department of neurology of our hospital. Two months before her referral visit, she experienced left optic neuritis, and her annualized relapse rate reached 0.6. She desired to switch from the injectable treatment to oral dimethyl fumarate (DMF) administration. At that time, she was found to be seropositive for MOG antibody, but after that had no relapses for more than five years. Moreover, her seropositivity for serum MOG-antibody turned out to be seronegative.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>DMF showed long-term effects on suppressing relapses in a pediatric patient with MOGAD, revealing its potential as a treatment option for such patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1551379","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:11:11Z","timestamp":1740460271000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Long-term suppression of relapses by dimethyl fumarate in a relapsing pediatric patient with myelin oligodendrocyte glycoprotein antibody\u2013associated disease manifesting as acute disseminated encephalomyelitis, unilateral optic neuritis, and seizure episodes"],"prefix":"10.3389","volume":"16","author":[{"given":"Masayuki","family":"Tahara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonari","family":"Awaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejpn.2020.10.006","article-title":"E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"103730","DOI":"10.1016\/j.msard.2022.103730","article-title":"Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration","volume":"60","author":"Tahara","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211038291","article-title":"Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension","volume":"28","author":"Pittock","year":"2022","journal-title":"Mult Scler"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200071","article-title":"Long-term efficacy of satralizumab in AQP4-igG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar","volume":"10","author":"Kleiter","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01292.x","article-title":"Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study","volume":"13","author":"Schimrigk","year":"2006","journal-title":"Eur J Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e6040","DOI":"10.7759\/cureus.6040","article-title":"Dimethyl fumarate was ineffective but not harmful for a patient with myelin oligodendrocyte glycoprotein antibody disease","volume":"11","author":"Warabi","year":"2019","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.625465","article-title":"Case report: anti-MOG antibody seroconversion accompanied by dimethyl fumarate treatment","volume":"12","author":"Takahashi","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"105829","DOI":"10.1016\/j.msard.2024.105829","article-title":"Clinical practice guidelines for multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease 2023 in Japan","volume":"90","author":"Niino","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2021.01.008","article-title":"A nation-wide survey of Japanese pediatric MOG antibody-associated diseases","volume":"43","author":"Azumagawa","year":"2021","journal-title":"Brain Dev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208303","article-title":"Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"96","author":"Virupakshaiah","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-333463","article-title":"Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse","volume":"95","author":"Trewin","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200035","article-title":"Temporal dynamics of MOG antibodies in children with acquired demyelinating syndrome","volume":"9","author":"Wendel","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/cen3.12771","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disorders: An overview","volume":"15","author":"Misu","year":"2024","journal-title":"Clin Exp Neuroimmunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.0489","article-title":"Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"79","author":"Chen","year":"2022","journal-title":"JAMA Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3593-24","article-title":"Successful maintenance therapy with intravenous immunoglobulin to reduce relapse attacks and steroid dose in a patient with refractory myelin oligodendrocyte glycoprotein antibody-positive optic neuritis","author":"Kamijo","year":"2024","journal-title":"Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1551379\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:11:14Z","timestamp":1740460274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1551379\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2025.1551379"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1551379","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"article-number":"1551379"}}